Time
About 75 minutes to complete
Loading…
CE/CME accredited
This educational activity is supported by an independent educational grant from Gilead Sciences, Inc.
Expert commentary from Tanyaporn Wansom and Ken Sujin Ho on HIV trends, PrEP, and rapid ART initiation and treatment selection.
Log in to start the CMEA MedSynapse account is required. After you log in, the full activity opens on this page. There are no prerequisites to participate in this activity.
About 75 minutes to complete
Those treating patients at risk and with HIV
This educational activity is supported by an independent educational grant from Gilead Sciences, Inc.
Expert commentary from Tanyaporn Wansom and Ken Sujin Ho on HIV trends, PrEP, and rapid ART initiation and treatment selection.
CE/CME accredited
Respond to the questions below to unlock the next part of the activity, covering HIV incidence trends, PrEP benefits and eligibility, and rapid ART initiation and treatment selection.
1. I counsel my patients in high-risk groups about HIV testing recommendations.
2. I discuss PrEP with individuals who may be at elevated risk of acquiring HIV.
3. A patient asks about starting PrEP. Which of the below would prevent initiation of PrEP at this time?
4. A patient is newly diagnosed with HIV and is ready to begin ART quickly. This patient has never used PrEP before. Results of HIV genotype, hepatitis B serology, and HLA-B*5701 testing are not yet available. Which of the following options includes appropriate regimens for rapid initiation of ART?
Answer every question to continue.
Watch the full commentary (59:22). The post-assessment unlocks when the video finishes.
Finish the video to continue.
You have completed this activity.
1. A patient asks about starting PrEP. Which of the below would prevent initiation of PrEP at this time?
2. A patient is newly diagnosed with HIV and is ready to begin ART quickly. This patient has never used PrEP before. Results of HIV genotype, hepatitis B serology, and HLA-B*5701 testing are not yet available. Which of the following options includes appropriate regimens for rapid initiation of ART?
3. I will now counsel my patients in high-risk groups about HIV testing recommendations.
4. I will now discuss PrEP with individuals who may be at elevated risk of acquiring HIV.
5. After participating in this activity, which of the following are you most likely to implement in your practice?
Answer every question to finish.
This educational activity is supported by an independent educational grant from Gilead Sciences, Inc.
Ask Me About HIV & PrEP: Education for Clinicians in Asia 2.0 [Thailand] may include presentations on drugs or devices, or use of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.
DKBmed is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by DKBmed of the uses, products, or techniques presented.
DKBmed takes responsibility for the content, quality, and scientific integrity of this activity.
All rights reserved – DKBmed. No part of this program may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
DKBmed fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
The target audience for this initiative is clinicians treating patients at risk and with HIV.
After completing this educational activity, you will be able to:
Associate Professor of Medicine
Medical Director, Pitt Men's Study, Multicenter AIDS Cohort Study
University of Pittsburgh MACS-WIHS CCS, Pittsburgh, PA, USA
Infectious Diseases Physician-Scientist
Thai Red Cross AIDS and Infectious Diseases Research Centre CRS
Bangkok, Thailand
The faculty have reported the following financial relationship(s) they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
| Name of faculty | Reported financial relationship |
|---|---|
| Ken Sujin Ho, MD, MPH | None |
| Tanyaporn Wansom, MD, PhD, MPP | None |
No one else in a position to control the content of this educational activity has disclosed a relevant financial interest or relationship with ineligible companies. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
We wish to acknowledge the following companies that have provided or pledged an educational grant in support of this activity. Please note that commercial support received is solely for the educational component of the activity and will not be used to provide food and beverage.
Gilead Sciences, Inc.
Copyright © DKBmed